Vladimir Coric, MD
Research & Publications
Biography
News
Coauthors
Selected Publications
- Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc AnalysisL’Italien G, Oikonomou E, Khera R, Potashman M, Beiner M, Maclaine G, Schmahmann J, Perlman S, Coric V. Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis. Neurology And Therapy 2024, 1-15. PMID: 38814532, DOI: 10.1007/s40120-024-00625-6.
- Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012)Dickson S, Rogula B, Dubow J, Kozauer N, Powell L, Potashman M, Crimin K, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Hendrix S, L’Italien G. Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204570.
- Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features (P1-1.007)Berg A, Lerner J, Millichap J, L’Italien G, Coric V, Potashman M. Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features (P1-1.007). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204827.
- Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018)Potashman M, Popoff E, Powell L, Beiner M, Mackenzie A, Coric V, Schmahmann J, L’Italien G. Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204549.
- Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson’s Disease Progression in Untreated Patients Using Parkinson’s Progression Markers Initiative Data (S2.004)L’Italien G, Dickson S, Rogula B, Dubow J, Kozauer N, Powell L, Potashman M, Crimin K, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Hendrix S. Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson’s Disease Progression in Untreated Patients Using Parkinson’s Progression Markers Initiative Data (S2.004). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204569.
- Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects (S5.006)Sevinsky H, Rozakis R, Nepomuceno T, Malatesta J, Awsare B, Ashbrenner E, Kaplita S, Gentile K, Hussey E, Qureshi I, Coric V, Bertz R. Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects (S5.006). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205022.
- No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole (P4-4.014)Bertz R, Rozakis R, Donohue M, Sevinsky H, Awsare B, Kaplita S, Hussey E, Qureshi I, Coric V. No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole (P4-4.014). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206134.
- Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders (P4-4.013)Qureshi I, Beiner M, Bertz R, Kaplita S, Yang R, Munivar A, Stock D, Wirtz V, Coric V. Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders (P4-4.013). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206182.
- Determinants of Health-related Quality of Life of Patients with Focal Epilepsy: A Systematic Literature Review (P9-1.016)Marcin C, Engelhart P, Lerner J, Dill D, L’Italien G, Coric V, Matsumoto J, Potashman M. Determinants of Health-related Quality of Life of Patients with Focal Epilepsy: A Systematic Literature Review (P9-1.016). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204828.
- The Phase 3 RESILIENT Study: Taldefgrobep Alfa in Spinal Muscular Atrophy (P2-11.008)Lair L, Qureshi I, Bechtold C, Durham S, Campbell D, Marin J, Coric V. The Phase 3 RESILIENT Study: Taldefgrobep Alfa in Spinal Muscular Atrophy (P2-11.008). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205020.
- Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia (S35.009)Beiner M, Powell L, Rogula B, Potashman M, Wirtz V, Schmahmann J, Perlman S, Coric V, L’Italien G. Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia (S35.009). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205167.
- Development of a Novel Composite Measure (SCACOMS) to Assess Disease Progression in Spinocerebellar Ataxia (P7-3.019)L’Italien G, Popoff E, Rogula B, Potashman M, Powell L, Beiner M, Coric V, Perlman S, Schmahmann J, Hendrix S. Development of a Novel Composite Measure (SCACOMS) to Assess Disease Progression in Spinocerebellar Ataxia (P7-3.019). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205169.
- Automated Video-based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects with Spinocerebellar Ataxia (P6-3.014)Beiner M, Oikonomou E, L’Italien G, Khera R, Potashman M, Schmahmann J, Perlman S, Coric V. Automated Video-based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects with Spinocerebellar Ataxia (P6-3.014). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205170.
- Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates (S43.004)Bunin A, Lee S, Kazmierski W, McGrath K, Rossi A, Nicholson S, Dubowchik G, Dierks E, Sharpe N, Pirman D, Car B, Qureshi I, Coric V, Spiegel D. Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates (S43.004). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206715.
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects (P4-4.012)Sevinsky H, Awsare B, Rozakis R, Gentile K, Mydlow P, Ashbrenner E, Ham R, Stock D, Qureshi I, Coric V, Bertz R. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects (P4-4.012). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205210.
- Population Pharmacokinetic Modeling of Riluzole After Administration of a Next Generation Prodrug Troriluzole (S3.007)Bertz R, Dumitrescu T, Wu Y, Jeong A, Sevinsky H, Qureshi I, Coric V. Population Pharmacokinetic Modeling of Riluzole After Administration of a Next Generation Prodrug Troriluzole (S3.007). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205212.
- Association of Anti-inflammatory Therapy Use with the Incidence of Parkinson’s Disease: A Person-Time Analysis Among Patients with Autoimmune Diseases (S2.003)Haas J, Potashman M, Pandit A, Stafkey-Mailey D, Coric V, Singer W, L’Italien G. Association of Anti-inflammatory Therapy Use with the Incidence of Parkinson’s Disease: A Person-Time Analysis Among Patients with Autoimmune Diseases (S2.003). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204573.
- Prognostic value of plasma biomarkers in a clinical trial of mild‐to‐moderate Alzheimer’s DiseaseQiu Y, Messer K, Jacobs D, Salmon D, Kaplita S, Wellington C, Stukas S, Askew B, Brewer J, Brody M, Donahue L, Drake J, Grossman K, Hendrix S, Jicha G, Leger G, Porsteinsson A, Shadyab A, Taylor C, Thomas R, van Dyck C, Zhang J, Coric V, Qureshi I, Feldman H, Group A. Prognostic value of plasma biomarkers in a clinical trial of mild‐to‐moderate Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.076047.
- P04 Taldefgrobep alfa: preclinical and clinical data supporting the phase 3 RESILIENT study in spinal muscular atrophyLair L, Qureshi I, Bechtold C, Heller L, Durham S, Campbell D, Marin J, Chen K, Coric V. P04 Taldefgrobep alfa: preclinical and clinical data supporting the phase 3 RESILIENT study in spinal muscular atrophy. Neuromuscular Disorders 2023, 33: s163. DOI: 10.1016/j.nmd.2023.07.381.
- Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported OutcomesPotashman M, Mize M, Beiner M, Pierce S, Coric V, Schmahmann J. Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported Outcomes. The Cerebellum 2022, 22: 1257-1273. PMID: 36495470, PMCID: PMC10657309, DOI: 10.1007/s12311-022-01494-1.
- Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)Powell L, L’Italien G, Popoff E, Johnston K, O’Sullivan F, Harris L, Croop R, Coric V, Lipton R. Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305). Advances In Therapy 2022, 40: 585-600. PMID: 36417057, PMCID: PMC9898331, DOI: 10.1007/s12325-022-02369-x.
- Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trialCroop R, Madonia J, Stock D, Thiry A, Forshaw M, Murphy A, Coric V, Lipton R. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial. Headache The Journal Of Head And Face Pain 2022, 62: 1153-1163. PMID: 36239038, PMCID: PMC9827820, DOI: 10.1111/head.14389.
- Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/HarmJohnston K, Powell L, Popoff E, Harris L, Croop R, Coric V, L’Italien G. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm. The Clinical Journal Of Pain 2022, 38: 680-685. PMID: 36125279, PMCID: PMC9555761, DOI: 10.1097/ajp.0000000000001072.
- A stated preference survey to explore patient preferences for novel preventive migraine treatmentsHubig L, Smith T, Chua G, Lloyd A, Powell L, Johnston K, Harris L, L'Italien G, Coric V, Lo S. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache The Journal Of Head And Face Pain 2022, 62: 1187-1197. PMID: 36047857, PMCID: PMC9826196, DOI: 10.1111/head.14386.
- Measuring interictal burden among people affected by migraine: a descriptive survey studyHubig L, Smith T, Williams E, Powell L, Johnston K, Harris L, L’Italien G, Coric V, Lloyd A, Lo S. Measuring interictal burden among people affected by migraine: a descriptive survey study. The Journal Of Headache And Pain 2022, 23: 97. PMID: 35941572, PMCID: PMC9358846, DOI: 10.1186/s10194-022-01467-z.
- Real-World experience of interictal burden and treatment in migraine: a qualitative interview studyLo S, Gallop K, Smith T, Powell L, Johnston K, Hubig L, Williams E, Coric V, Harris L, L’Italien G, Lloyd A. Real-World experience of interictal burden and treatment in migraine: a qualitative interview study. The Journal Of Headache And Pain 2022, 23: 65. PMID: 35676636, PMCID: PMC9174626, DOI: 10.1186/s10194-022-01429-5.
- Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002)Jensen C, Thiry A, Kim E, Lovergren M, Croop R, Coric V, L‘Italien G, Lipton R. Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.873.
- An Open-label, Intermediate-sized, Expanded Access Protocol of Rimegepant in the Acute Treatment of Migraine (P2-2.006)Croop R, Shiovitz T, Khan A, Noonan T, Kaplita S, Seymour E, Jensen C, Coric V. An Open-label, Intermediate-sized, Expanded Access Protocol of Rimegepant in the Acute Treatment of Migraine (P2-2.006). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.874.
- Effect of Strong P-gp and BCRP Inhibition, Using Cyclosporine and Quinidine as Probes, on the Pharmacokinetics of Oral Rimegepant 75 mg in Healthy Subjects (P2-2.001)Bertz R, Anderson M, Collins J, Stringfellow J, Madonia J, Bharwaj R, Finley J, Stock D, Coric V, Croop R. Effect of Strong P-gp and BCRP Inhibition, Using Cyclosporine and Quinidine as Probes, on the Pharmacokinetics of Oral Rimegepant 75 mg in Healthy Subjects (P2-2.001). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.877.
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Intranasal Zavegepant in Healthy Adults (S31.004)Bertz R, Donohue M, Madonia J, Bhardwaj R, Stringfellow J, Anderson M, Stock D, Morris B, Coric V, Croop R. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Intranasal Zavegepant in Healthy Adults (S31.004). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1003.
- Reduction in Period Prevalence of Medication Overuse Headache Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study (P12-2.003)L’Italien G, Harris L, Mohajer A, Scripture J, Coric V, Rosen N. Reduction in Period Prevalence of Medication Overuse Headache Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study (P12-2.003). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.3698.
- Reduction in Opioid Prescription Fills and Morphine Milligram Equivalent Dispensed Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study (S31.010)Mohajer A, Scripture J, L'Italien G, Harris L, Coric V, Rosen N. Reduction in Opioid Prescription Fills and Morphine Milligram Equivalent Dispensed Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study (S31.010). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.3807.
- Low Levels of Rimegepant in Breast Milk After a Single 75-mg Dose (P1-1.Virtual)Baker T, Croop R, Kamen L, Stock D, Ivans A, Bhardwaj R, Anderson M, Madonia J, Stringfellow J, Bertz R, Coric V, Hale T. Low Levels of Rimegepant in Breast Milk After a Single 75-mg Dose (P1-1.Virtual). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.658.
- Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United StatesHarris L, L’Italien G, Kumar A, Seelam P, LaVallee C, Coric V, Lipton R. Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States. Headache The Journal Of Head And Face Pain 2022, 62: 473-481. PMID: 35343590, PMCID: PMC9313575, DOI: 10.1111/head.14289.
- P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy SubjectsBhardwaj R, Collins J, Stringfellow J, Madonia J, Anderson M, Finley J, Stock D, Coric V, Croop R, Bertz R. P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. Clinical Pharmacology In Drug Development 2022, 11: 889-897. PMID: 35304977, PMCID: PMC9311059, DOI: 10.1002/cpdd.1088.
- Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating WomenBaker T, Croop R, Kamen L, Price P, Stock D, Ivans A, Bhardwaj R, Anderson M, Madonia J, Stringfellow J, Bertz R, Coric V, Hale T. Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women. Breastfeeding Medicine 2022, 17: 277-282. PMID: 35049333, PMCID: PMC8972016, DOI: 10.1089/bfm.2021.0250.
- Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)Johnston K, Harris L, Powell L, Popoff E, Coric V, L’Italien G, Schreiber C. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201). The Journal Of Headache And Pain 2022, 23: 10. PMID: 35038983, PMCID: PMC8903552, DOI: 10.1186/s10194-021-01378-5.
- POSC170 Decreased Opioid Use in Migraine Patients Following Rimegepant Initiation: A Real-World AnalysisMohajer A, Scripture J, Harris L, Rosen N, Coric V, Croop R, L'Italien G. POSC170 Decreased Opioid Use in Migraine Patients Following Rimegepant Initiation: A Real-World Analysis. Value In Health 2022, 25: s134. DOI: 10.1016/j.jval.2021.11.644.
- POSC202 Estimated Migraine Patient Population in England Progressing Beyond First-Line Acute ManagementHarris L, L'Italien G, Croop R, Coric V, Robbins J, Woolley J, OConnell T. POSC202 Estimated Migraine Patient Population in England Progressing Beyond First-Line Acute Management. Value In Health 2022, 25: s140. DOI: 10.1016/j.jval.2021.11.675.
- Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label studyL’Italien G, Popoff E, Johnston K, McGrath D, Conway C, Powell L, Harris L, Kowalczyk N, Croop R, Coric V. Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study. Cephalalgia Reports 2022, 5: 25158163221075596. DOI: 10.1177/25158163221075596.
- Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving RimegepantJohnston K, L’Italien G, Popoff E, Powell L, Croop R, Thiry A, Harris L, Coric V, Lipton R. Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant. Advances In Therapy 2021, 38: 5209-5220. PMID: 34455556, PMCID: PMC8478726, DOI: 10.1007/s12325-021-01897-2.
- Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysisJohnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L’Italien G, Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Review Of Pharmacoeconomics & Outcomes Research 2021, 22: 155-166. PMID: 34148501, DOI: 10.1080/14737167.2021.1945444.
- Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migrainePopoff E, Johnston K, Croop R, Thiry A, Harris L, Powell L, Coric V, L’Italien G, Moren J. Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine. Headache The Journal Of Head And Face Pain 2021, 61: 906-915. PMID: 34021585, PMCID: PMC8361942, DOI: 10.1111/head.14128.
- Novel acute therapies in the treatment of migraine: impact of re-dosing on cost–utility outcomesJohnston K, L'italien G, Harris L, Deighton A, Popoff E, Croop R, Coric V. Novel acute therapies in the treatment of migraine: impact of re-dosing on cost–utility outcomes. Journal Of Medical Economics 2021, 24: 512-513. PMID: 33843409, DOI: 10.1080/13696998.2021.1915600.
- A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adultsCroop R, Ivans A, Anderson M, Stringfellow J, Bertz R, Hanna M, Healy F, Stock D, Coric V, Lipton R. A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Reports 2021, 4: 25158163211007922. DOI: 10.1177/25158163211007922.
- Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trialCroop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet 2020, 397: 51-60. PMID: 33338437, DOI: 10.1016/s0140-6736(20)32544-7.
- Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for MigraineBerman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry A, Conway C, Coric V, Lipton R. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Headache The Journal Of Head And Face Pain 2020, 60: 1734-1742. PMID: 32799325, PMCID: PMC7496574, DOI: 10.1111/head.13930.
- Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials (1212)Levin M, Buse D, Blumenfeld A, Lipton R, Stock E, Thiry A, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials (1212). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1212.
- Rimegepant 75 mg Demonstrates Safety and Tolerability Similar to Placebo With No Effects of Age, Sex, or Race in 3 Phase 3 Trials (1609)Schim J, Hutchinson S, Lipton R, Stock E, Thiry A, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg Demonstrates Safety and Tolerability Similar to Placebo With No Effects of Age, Sex, or Race in 3 Phase 3 Trials (1609). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1609.
- Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine (1793)McGinley J, L’Italien G, Thiry A, Croop R, Coric V, Lipton R. Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine (1793). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1793.
- Acute Treatment of Migraine with Oral Rimegepant 75 mg Confers Robust Improvement in Absenteeism, Presenteeism and Productivity: Results from a One Year, Open-Label, Safety Study (BHV3000-201) (1864)L’Italien G, Croop R, Stock E, Thiry A, Rosenthal H, Lovegren M, Jensen C, Coric V, Lipton R. Acute Treatment of Migraine with Oral Rimegepant 75 mg Confers Robust Improvement in Absenteeism, Presenteeism and Productivity: Results from a One Year, Open-Label, Safety Study (BHV3000-201) (1864). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1864.
- Acute Treatment with Oral Rimegepant 75mg Reduces Migraine-Related Disability: Results from a One Year, Open-Label Safety Study (BHV3000-201) (1926)L’Italien G, Croop R, Stock E, Thiry A, Lovegren M, Cowie K, Jensen C, Coric V, Lipton R. Acute Treatment with Oral Rimegepant 75mg Reduces Migraine-Related Disability: Results from a One Year, Open-Label Safety Study (BHV3000-201) (1926). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1926.
- Acute Treatment of Migraine with Oral Rimegepant 75 mg Improves Health Related Quality of Life: Results from a Long-Term, Open-Label Safety Study (BHV3000-201) (1943)Harris L, L’Italien G, Croop R, Stock E, Thiry A, Cowrie K, Lovegren M, Jensen C, Coric V, Lipton R. Acute Treatment of Migraine with Oral Rimegepant 75 mg Improves Health Related Quality of Life: Results from a Long-Term, Open-Label Safety Study (BHV3000-201) (1943). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1943.
- Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP Monoclonal Antibodies (mAb) Examining Health-related Quality of Life (HRQoL). (1951)Popoff E, Johnston K, Harris L, Thiry A, Croop R, Coric V, L’Italien G. Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP Monoclonal Antibodies (mAb) Examining Health-related Quality of Life (HRQoL). (1951). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1951.
- Migraine Patients Exhibit Increased Relative Risk for Medication Overuse Headache with Sustained Triptan Treatment – Results from a Real-World Claims Analysis (1976)Harris L, Croop R, Coric V, L’Italien G, Dandona H, Li Y. Migraine Patients Exhibit Increased Relative Risk for Medication Overuse Headache with Sustained Triptan Treatment – Results from a Real-World Claims Analysis (1976). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1976.
- Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials (2091)Pavlovic J, Dodick D, Newman L, Lipton R, Stock E, Thiry A, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials (2091). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2091.
- Rimegepant 75 mg Is More Effective for Migraine Than Nonsteroidal Anti-inflammatory Drugs: Post Hoc Analysis of Data From 2 Phase 3 Trials (2107)Turner I, Buse D, Blumenfeld A, Stock E, Stock D, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg Is More Effective for Migraine Than Nonsteroidal Anti-inflammatory Drugs: Post Hoc Analysis of Data From 2 Phase 3 Trials (2107). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2107.
- Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112)Jensen C, Croop R, Lipton R, Stock E, Thiry A, Conway C, Lovegren M, Coric V, L’Italien G. Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2112.
- Rimegepant is Effective for the Acute Treatment of Migraine in Patients Who Have Discontinued or Currently Use Triptans: Results from 3 Phase 3 Clinical Trials (2114)Croop R, Jensen C, Thiry A, Stock E, Conway C, Morris B, Coric V, Lipton R. Rimegepant is Effective for the Acute Treatment of Migraine in Patients Who Have Discontinued or Currently Use Triptans: Results from 3 Phase 3 Clinical Trials (2114). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2114.
- Rimegepant Has No Clinically Relevant Effect on ECG parameters at Therapeutic and Supratherapeutic Doses: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects (2117)Hanna M, Coric V, Stringfellow J, Ivans A, Croop R. Rimegepant Has No Clinically Relevant Effect on ECG parameters at Therapeutic and Supratherapeutic Doses: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects (2117). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2117.
- Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126)Ivans A, Stringfellow J, Coric V, Croop R. Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2126.
- Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays (2141)Conway C, Croop R, Dubowchik G, Coric V, Lipton R. Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays (2141). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2141.
- Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145)Conway C, Dubowchik G, Croop R, Coric V. Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2145.
- Rimegepant 75 mg Provides Early and Sustained Relief of Migraine With a Single Dose: Results from 3 Phase 3 Clinical Trials (2366)Pavlovic J, Dodick D, Friedman D, Tepper S, Newman L, Lipton R, Stock E, Thiry A, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg Provides Early and Sustained Relief of Migraine With a Single Dose: Results from 3 Phase 3 Clinical Trials (2366). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2366.
- Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402)McAllister P, Berman G, Kudrow D, Smith T, Lipton R, Stock E, Stock D, Conway C, Jensen C, Morris B, Coric V, Croop R. Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2402.
- Oral Rimegepant Produces No Significant Effect on Blood Pressure When Administered Concomitantly with SC Sumatriptan (4007)Hanna M, Ivans A, Stringfellow J, Jensen C, Coric V, Croop R. Oral Rimegepant Produces No Significant Effect on Blood Pressure When Administered Concomitantly with SC Sumatriptan (4007). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4007.
- Comparative Efficacy and Safety of Rimegepant Versus Ubrogepant and Lasmiditan for Acute Treatment of Migraine: A Network Meta-analysis (NMA) (4369)Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L’Italien G. Comparative Efficacy and Safety of Rimegepant Versus Ubrogepant and Lasmiditan for Acute Treatment of Migraine: A Network Meta-analysis (NMA) (4369). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4369.
- Oral Rimegepant 75 mg Is Well-tolerated When Used Concomitantly with Injectable Anti-CGRP Monoclonal Antibodies: Results From a Multicenter, Long-term, Open-label Safety Study (4553)Berman G, Kudrow D, Halverson P, Lipton R, Lovegren M, Thiry A, Jensen C, Zhang Y, Stock E, Conway C, Croop R, Coric V. Oral Rimegepant 75 mg Is Well-tolerated When Used Concomitantly with Injectable Anti-CGRP Monoclonal Antibodies: Results From a Multicenter, Long-term, Open-label Safety Study (4553). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4553.
- Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP-targeted Monoclonal Antibodies Examining Monthly Migraine Days in the Treatment of Migraine (4563)Popoff E, Johnston K, Croop R, Thiry A, Harris L, Coric V, L’Italien G. Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP-targeted Monoclonal Antibodies Examining Monthly Migraine Days in the Treatment of Migraine (4563). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4563.
- Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine (Study 201) (4829)Croop R, Berman G, Kudrow D, Mullin K, Stock E, Thiry A, Conway C, Jensen C, Lovegren M, Coric V, Lipton R. Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine (Study 201) (4829). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4829.
- Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsymLongo D, Shoda L, Howell B, Coric V, Berman R, Qureshi I. Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym. Toxicological Sciences 2020, 175: 292-300. PMID: 32040174, PMCID: PMC7253195, DOI: 10.1093/toxsci/kfaa019.
- Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapyMullin K, Kudrow D, Croop R, Lovegren M, Conway C, Coric V, Lipton R. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 2020, 94: 10.1212/wnl.0000000000008944. PMID: 31932515, PMCID: PMC7526667, DOI: 10.1212/wnl.0000000000008944.
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trialCroop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet 2019, 394: 737-745. PMID: 31311674, DOI: 10.1016/s0140-6736(19)31606-x.
- Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for MigraineLipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. New England Journal Of Medicine 2019, 381: 142-149. PMID: 31291516, DOI: 10.1056/nejmoa1811090.
- Results from the Long-Term Open Label Extension Phase Analyses of BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia (P1.8-001)Beiner M, Wirtz V, Coric V, Berman R, L’Italien G. Results from the Long-Term Open Label Extension Phase Analyses of BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia (P1.8-001). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p1.8-001.
- A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005)Qureshi I, Coric V, Gentile K, Larouche R, Tanguay M, Berman R. A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.s5.005.
- Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical TrialCoric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. JAMA Neurology 2015, 72: 1324-1333. PMID: 26414022, DOI: 10.1001/jamaneurol.2015.0607.
- Efficacy of Modified Cognitive Interviewing, Compared to Human Judgments in Detecting Deception Related to Bio-threat ActivitiesMorgan C, Rabinowitz Y, Hilts D, Weller C, Coric V. Efficacy of Modified Cognitive Interviewing, Compared to Human Judgments in Detecting Deception Related to Bio-threat Activities. Journal Of Strategic Security 2013, 6: 100-119. DOI: 10.5038/1944-0472.6.3.9.
- Sheehan Suicidality Tracking Scale (S-STS): Reliability, convergent and discriminative validity in young Italian adultsPreti A, Sheehan D, Coric V, Distinto M, Pitanti M, Vacca I, Siddi A, Masala C, Petretto D. Sheehan Suicidality Tracking Scale (S-STS): Reliability, convergent and discriminative validity in young Italian adults. Comprehensive Psychiatry 2013, 54: 842-849. PMID: 23618606, DOI: 10.1016/j.comppsych.2013.03.012.
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer DiseaseCoric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM. Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease. JAMA Neurology 2012, 69: 1430-1440. PMID: 22892585, DOI: 10.1001/archneurol.2012.2194.
- Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorderCoric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang S, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG. Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder. Depression And Anxiety 2010, 27: 417-425. PMID: 20455246, DOI: 10.1002/da.20695.
- Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder.Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder. Innov Clin Neurosci 2009, 6: 26-31. PMID: 19724740, PMCID: PMC2719443.
- Response to Chamberlain et al. Re: Systematic Review: Pharmacological and Behavioral Treatments for TrichotillomaniaBloch M, Landeros-Weisenberger A, Dombrowski P, Nudel J, Pittenger C, Leckman J, Kelmendi B, Wegner R, Coric V. Response to Chamberlain et al. Re: Systematic Review: Pharmacological and Behavioral Treatments for Trichotillomania. Biological Psychiatry 2008, 63: e34-e35. DOI: 10.1016/j.biopsych.2008.01.022.
- Systematic Review: Pharmacological and Behavioral Treatment for TrichotillomaniaBloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J, Pittenger C, Leckman JF, Coric V. Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania. Biological Psychiatry 2007, 62: 839-846. PMID: 17727824, DOI: 10.1016/j.biopsych.2007.05.019.
- Erratum: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorderBloch M, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken M, Leckman J. Erratum: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11: 795-795. DOI: 10.1038/sj.mp.4001859.
- Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder.Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. The Journal Of Clinical Psychiatry 2005, 66: 1492-3. PMID: 16420092, DOI: 10.4088/jcp.v66n1121d.
- Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label TrialCoric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial. Biological Psychiatry 2005, 58: 424-428. PMID: 15993857, DOI: 10.1016/j.biopsych.2005.04.043.
- 231. Neuroendocrine and psychobiological responses to uncontrollable stressMorgan C, Coric V, Zimolo Z, Hoyt G, Wang S, Hazlett G, Charney D. 231. Neuroendocrine and psychobiological responses to uncontrollable stress. Biological Psychiatry 2000, 47: s70. DOI: 10.1016/s0006-3223(00)00495-9.
- 459. Psycho-biological indices of special operations selectionMorgan C, Simpson P, Hazlett G, Coric V, Charney D. 459. Psycho-biological indices of special operations selection. Biological Psychiatry 2000, 47: s140. DOI: 10.1016/s0006-3223(00)00729-0.
- Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phaseCoric V, Oren D, Wolkenberg F, Kravitz R. Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phase. Journal Of Neurology Neurosurgery & Psychiatry 1998, 65: 245. PMID: 9703180, PMCID: PMC2170185, DOI: 10.1136/jnnp.65.2.245.